Immunogenicity and Safety Study of Half Dose of Moderna COVID-19 Vaccine Booster Heterologous in Adult Subjects in Indonesia. To compare the immunogenicity after booster dose between AstraZeneca and Sinovac priming group
Outcome
To evaluate the antibody titres before and 28 days (+7 days) after booster dose with half booster dose of mRNA-1273
Sponsor
Kementerian Kesehatan Republik Indonesia
Date
-
Subjects
200 subjects